Literature DB >> 24650018

Both bone marrow-derived and non-bone marrow-derived cells contribute to AIM2 and NLRP3 inflammasome activation in a MyD88-dependent manner in dietary steatohepatitis.

Timea Csak1, Arun Pillai, Michal Ganz, Dora Lippai, Jan Petrasek, Jin-Kyu Park, Karen Kodys, Angela Dolganiuc, Evelyn A Kurt-Jones, Gyongyi Szabo.   

Abstract

BACKGROUND & AIMS: Inflammation promotes the progression of non-alcoholic steatohepatitis (NASH). Toll-like receptor 4 (TLR4) and TLR9 activation through myeloid differentiation primary response gene 88 (MyD88) and production of mature interleukin-1β (IL-1β) via inflammasome activation contribute to steatohepatitis. Here, we investigated the inter-relationship between TLR signalling and inflammasome activation in dietary steatohepatitis.
METHODS: Wild type (WT), TLR4- and MyD88-deficient (KO) mice received methionine-choline-deficient (MCD) or -supplemented (MCS) diets for 5 weeks and a subset was challenged with TLR9 ligand CpG-DNA.
RESULTS: TLR4, TLR9, AIM2 (absent in melanoma 2) and NLRP3 (NLR family pyrin domain containing 3) inflammasome mRNA, and mature IL-1β protein levels were increased in MCD diet-induced steatohepatitis compared to MCS controls. TLR9 stimulation resulted in greater up-regulation of the DNA-sensing AIM2 expression and IL-1β production in livers of MCD compared to MCS diet-fed mice. High mobility group box 1 (HMGB1), a TLR9-activating danger molecule and phospho-HMGB1 protein levels were also increased in livers of MCD diet-fed mice. MyD88- but not TLR4-deficiency prevented up-regulation of AIM2, NLRP3 mRNA and IL-1β protein production in dietary steatohepatitis. Selective MyD88 deficiency either in bone marrow (BM)-derived or non-BM-derived cells attenuated hepatic up-regulation of inflammasome mRNA, caspase-1 activation and IL-1β protein production, but only BM-derived cell-specific MyD88-deficiency attenuated liver injury.
CONCLUSIONS: Our data demonstrate that both bone marrow-derived and non-BM-derived cells contribute to inflammasome activation in a MyD88-dependent manner in dietary steatohepatitis. We show that AIM2 inflammasome expression and activation are further augmented by TLR9 ligands in dietary steatohepatitis.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  AIM2; HMGB1; IL-1β; MyD88; NLRP3; TLR4; TLR9; caspase-1; inflammasome; non-alcoholic steatohepatitis

Mesh:

Substances:

Year:  2014        PMID: 24650018      PMCID: PMC4169310          DOI: 10.1111/liv.12537

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  45 in total

1.  In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease.

Authors:  Anna Wieckowska; Nizar N Zein; Lisa M Yerian; A Rocio Lopez; Arthur J McCullough; Ariel E Feldstein
Journal:  Hepatology       Date:  2006-07       Impact factor: 17.425

2.  The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response.

Authors:  Daniel A Muruve; Virginie Pétrilli; Anne K Zaiss; Lindsay R White; Sharon A Clark; P Joel Ross; Robin J Parks; Jurg Tschopp
Journal:  Nature       Date:  2008-02-20       Impact factor: 49.962

3.  Calcium/calmodulin-dependent protein kinase (CaMK) IV mediates nucleocytoplasmic shuttling and release of HMGB1 during lipopolysaccharide stimulation of macrophages.

Authors:  Xianghong Zhang; David Wheeler; Ying Tang; Lanping Guo; Richard A Shapiro; Thomas J Ribar; Anthony R Means; Timothy R Billiar; Derek C Angus; Matthew R Rosengart
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

4.  Caspase-1 activation of lipid metabolic pathways in response to bacterial pore-forming toxins promotes cell survival.

Authors:  Laure Gurcel; Laurence Abrami; Stephen Girardin; Jurg Tschopp; F Gisou van der Goot
Journal:  Cell       Date:  2006-09-22       Impact factor: 41.582

5.  Bone marrow-derived immune cells mediate sensitization to liver injury in a myeloid differentiation factor 88-dependent fashion.

Authors:  Istvan Hritz; Arumugam Velayudham; Angela Dolganiuc; Karen Kodys; Pranoti Mandrekar; Evelyn Kurt-Jones; Gyongyi Szabo
Journal:  Hepatology       Date:  2008-10       Impact factor: 17.425

Review 6.  Toll-like receptors and adaptor molecules in liver disease: update.

Authors:  Ekihiro Seki; David A Brenner
Journal:  Hepatology       Date:  2008-07       Impact factor: 17.425

Review 7.  Animal models of NASH: getting both pathology and metabolic context right.

Authors:  Claire Z Larter; Matthew M Yeh
Journal:  J Gastroenterol Hepatol       Date:  2008-08-21       Impact factor: 4.029

8.  Acetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3 inflammasome.

Authors:  Avlin B Imaeda; Azuma Watanabe; Muhammad A Sohail; Shamail Mahmood; Mehdi Mohamadnejad; Fayyaz S Sutterwala; Richard A Flavell; Wajahat Z Mehal
Journal:  J Clin Invest       Date:  2009-01-26       Impact factor: 14.808

9.  A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA.

Authors:  Stanimir Ivanov; Ana-Maria Dragoi; Xin Wang; Corrado Dallacosta; Jennifer Louten; Giovanna Musco; Giovanni Sitia; George S Yap; Yinsheng Wan; Christine A Biron; Marco E Bianchi; Haichao Wang; Wen-Ming Chu
Journal:  Blood       Date:  2007-06-04       Impact factor: 22.113

10.  Inside, outside, upside down: damage-associated molecular-pattern molecules (DAMPs) and redox.

Authors:  Anna Rubartelli; Michael T Lotze
Journal:  Trends Immunol       Date:  2007-09-12       Impact factor: 16.687

View more
  29 in total

Review 1.  AIM2 inflammasome in infection, cancer, and autoimmunity: Role in DNA sensing, inflammation, and innate immunity.

Authors:  Si Ming Man; Rajendra Karki; Thirumala-Devi Kanneganti
Journal:  Eur J Immunol       Date:  2015-12-28       Impact factor: 5.532

2.  Exercise suppresses NLRP3 inflammasome activation in mice with diet-induced NASH: a plausible role of adropin.

Authors:  Wenqi Yang; Ling Liu; Yuan Wei; Chunlu Fang; Shujing Liu; Fu Zhou; Yaping Li; Ge Zhao; Ziyi Guo; Yuan Luo; Liangming Li
Journal:  Lab Invest       Date:  2020-12-02       Impact factor: 5.662

Review 3.  Innate immune signaling and gut-liver interactions in non-alcoholic fatty liver disease.

Authors:  Veerle Bieghs; Christian Trautwein
Journal:  Hepatobiliary Surg Nutr       Date:  2014-12       Impact factor: 7.293

4.  Sevoflurane attenuates cardiomyocyte apoptosis by mediating the miR-219a/AIM2/TLR4/MyD88 axis in myocardial ischemia/reperfusion injury in mice.

Authors:  Yan Li; Na Xing; Jingjing Yuan; Jianjun Yang
Journal:  Cell Cycle       Date:  2020-05-23       Impact factor: 4.534

Review 5.  Immunoregulation by lipids during the development of non-alcoholic steatohepatitis.

Authors:  Pierluigi Ramadori; Daniela Kroy; Konrad L Streetz
Journal:  Hepatobiliary Surg Nutr       Date:  2015-02       Impact factor: 7.293

6.  The P2X7R-NLRP3 and AIM2 Inflammasome Platforms Mark the Complexity/Severity of Viral or Metabolic Liver Damage.

Authors:  Chiara Rossi; Antonio Salvati; Mariarosaria Distaso; Daniela Campani; Francesco Raggi; Edoardo Biancalana; Domenico Tricò; Maurizia Rossana Brunetto; Anna Solini
Journal:  Int J Mol Sci       Date:  2022-07-04       Impact factor: 6.208

Review 7.  Inflammasome activation and function in liver disease.

Authors:  Gyongyi Szabo; Jan Petrasek
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-06-09       Impact factor: 46.802

Review 8.  Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies.

Authors:  Giovanni Musso; Maurizio Cassader; Roberto Gambino
Journal:  Nat Rev Drug Discov       Date:  2016-01-22       Impact factor: 84.694

9.  Role of FXR in Liver Inflammation during Nonalcoholic Steatohepatitis.

Authors:  Laura E Armstrong; Grace L Guo
Journal:  Curr Pharmacol Rep       Date:  2017-02-21

10.  NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice.

Authors:  Auvro R Mridha; Alexander Wree; Avril A B Robertson; Matthew M Yeh; Casey D Johnson; Derrick M Van Rooyen; Fahrettin Haczeyni; Narci C-H Teoh; Christopher Savard; George N Ioannou; Seth L Masters; Kate Schroder; Matthew A Cooper; Ariel E Feldstein; Geoffrey C Farrell
Journal:  J Hepatol       Date:  2017-02-03       Impact factor: 25.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.